ARCHIVES

NCI blocked groups from phase III Iressa studies.

This article is from The Cancer Letter archive.

Vol. 30 No. 18 | April 30, 2004

Download PDF Visit The Full Archive

Related Articles

Young Scientists Get Their Share Of NCI Grants

March 29, 1974

FDA Committee Approves NDA for Mitxantrone

March 21, 1986

Clinical Trials, Centers Would Be First In Line For Money Added To Budget, Broder Tells Congress

March 31, 1989

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

January 14, 2005

Poland Knights Peto, Boyle; Mihich Wins Tomasi Award.

February 2, 2001

FDA Approves Xeloda For Colon Cancer; Phase III Data Not Reviewed By ODAC.

May 4, 2001